MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

LSKL, Inhibitor of Thrombospondin (TSP-1)

CAS No. : 283609-79-0

MCE 国际站：LSKL, Inhibitor of Thrombospondin (TSP-1)

产品活性：LSKL, Inhibitor of Thrombospondin (TSP-1) 是一种衍生自 LAP-TGFβ 的四肽，是一种竞争性的 TGF-β1 拮抗剂。LSKL, Inhibitor of Thrombospondin (TSP-1) 抑制 TSP-1 与 LAP 的结合并减轻肾间质纤维化和肝纤维化。LSKL, Inhibitor of Thrombospondin (TSP-1) 通过抑制 TSP-1 介导的 TGF-β1 活性来抑制蛛网膜下纤维化，防止慢性脑积水的发生并改善蛛网膜下腔出血后的长期神经认知缺陷。LSKL, Inhibitor of Thrombospondin (TSP-1) 可以轻松穿越血脑屏障。

研究领域：TGF-beta/Smad

作用靶点：TGF-β Receptor

In Vitro: The KTFR sequence from ADAMTS1 is responsible for the interaction with the LSKL, Inhibitor of Thrombospondin (TSP-1) (LSKL peptide) from the latent form of TGF-β, leading to its activation. There is a stable binding mode between LSKL, Inhibitor of Thrombospondin (TSP-1) and ADAMTS1 KTFR sequence, characterized by 3 salt bridges and 2 hydrogen bonds.

In Vivo: LSKL, Inhibitor of Thrombospondin (TSP-1) (1 mg/kg; intraperitoneal injection; male Sprague-Dawley rats) is protective against subarachnoid fibrosis, attenuates ventriculomegaly and effectively suppresses hydrocephalus. LSKL, Inhibitor of Thrombospondin (TSP-1) treatment inhibits TGF-β1 activity and subsequent Smad2/3 signaling.
LSKL, Inhibitor of Thrombospondin (TSP-1) (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL, Inhibitor of Thrombospondin (TSP-1) successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL, Inhibitor of Thrombospondin (TSP-1) accelerates hepatocyte proliferation after hepatectomy.

相关产品：Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  TGF-beta/Smad Compound Library  |  Anti-Cancer Compound Library  |  CNS-Penetrant Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Osteogenesis Compound Library  |  Cancer Stem Cells Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)  |  ML347  |  Nadecnemab  |  Zilurgisertib  |  TGFβRI-IN-3  |  Vactosertib  |  Itacnosertib  |  Trafermin  |  Maohuoside A  |  Metelimumab  |  Stamulumab  |  SB-505124 hydrochloride  |  K02288  |  J-1063  |  ALK5-IN-25  |  LY-364947  |  GW-6604  |  TP-008  |  ALK2-IN-4  |  Galunisertib  |  CJJ300  |  ALK5-IN-7  |  ALK5-IN-32  |  A 83-01  |  RepSox (GMP)  |  A 77-01  |  Dorsomorphin  |  OD36  |  BMS-986260

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-P0299

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。